Interventions

Experimental off label

Acarbose has extended lifespan in the National Institute on Aging’s mouse testing program, making it an interesting candidate for ageing research. Repeated animal results help justify investigation, but do not determine whether a diabetes medicine benefits people without diabetes or extends human life. Human clinical outcomes are the important next test of the longevity hypothesis. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Behavioral

Fine-particle air pollution contributes to cardiovascular and respiratory disease and premature death. Reducing exposure is therefore a health-protection issue with substantial population-level evidence. The benefit of a specific personal measure, such as a device or a change in routine, still depends on actual exposure reduction and should not be inferred solely from a general pollution statistic. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Behavioral

Alcohol contributes to several cancers and other serious health problems, and drinking less reduces exposure to those risks. The current public-health case is harm reduction, not using alcohol as a longevity tool. Older associations between moderate drinking and better health should not be read as proof that starting to drink improves health or lengthens life. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Prescription

Treating high blood pressure can prevent serious cardiovascular events. In SPRINT, more intensive treatment reduced cardiovascular events and deaths in the higher-risk adults studied. This is direct human outcome evidence, but the appropriate target depends on the person and the risks of treatment; the trial is not a universal target for everyone. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Behavioral

Reducing calorie intake without malnutrition has produced ageing-related effects in animals and improvements in some human disease-risk markers. Human studies such as CALERIE also highlight tradeoffs, including losses of bone or lean tissue. Changes in blood pressure, metabolism or ageing markers are not themselves proof of longer human life; nutrition and long-term outcomes remain central questions. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Accessible

Cold-water immersion is being studied for effects on stress, wellbeing and recovery. The research remains limited and uses varied methods, making broad claims difficult to assess. A short-term physiological response or improved wellbeing is not proof of slower ageing; meaningful long-term benefits and the balance of benefit and risk need separate evidence. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Accessible

Creatine has useful evidence for high-intensity exercise performance and adaptations to strength training. These outcomes can matter for physical capacity, but performance or lean-mass benefits do not demonstrate longer life. Its role on a longevity site is therefore mainly as a possible aid to maintaining function, with broader ageing claims requiring their own evidence. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Frontier

Epigenetic clocks estimate aspects of biological ageing from chemical patterns on DNA. Some estimates help predict later health outcomes, but they are measurement tools rather than treatments. A clock reading becoming younger is not automatically proof that an intervention prevents disease or extends life; that connection needs validation against outcomes people actually experience. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI-reviewed · not yet expert-reviewed

Oct 22, 2026

Behavioral

Regular physical activity has established benefits for heart health, physical function and independence as people age. The practical evidence covers aerobic activity, strength and balance, rather than one special longevity workout. Better function and lower disease risk are meaningful outcomes; they do not translate into a guaranteed number of extra years for an individual. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 27, 2026: “Physical Activity Interventions for Sleep Improvement and Sedative-Hypnotic Reduction in Middle-Aged and Older Adults: Investigating the Role of Sarcopenia”. Its implications have not yet been summarized in a source-checked review. Read update ↗

AI review not yet available

Frontier

Gene therapy changes gene activity or the properties of cells to treat a particular condition. Approved applications exist for specific diseases, but their success cannot be transferred automatically to experimental ageing targets. For longevity, the relevant questions are which tissue and pathway are changed, whether people gain meaningful health benefits, and what risks persist after treatment. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Prescription

These medicines have moved beyond weight-loss measurements to important clinical outcomes. Semaglutide has an FDA indication for reducing cardiovascular death, heart attack and stroke in adults with established cardiovascular disease and overweight or obesity. That is a benefit for a defined patient group, not evidence that these medicines extend life in otherwise healthy people. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 13, 2026: “Evidence-Based Longevity Interventions and Targeted Engagement (E.L.I.T.E.)”. Its implications have not yet been summarized in a source-checked review. Read update ↗

AI review not yet available

Prescription

Replacing a diagnosed hormone deficiency is different from giving growth hormone to counter normal ageing. Endocrine guidance does not establish growth-hormone enhancement as an anti-ageing intervention. Changes in body composition alone are not enough to demonstrate better health or longer life, and treatment effects and harms must be assessed together. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Accessible

Treating hearing loss improves access to sound and communication. In the ACHIEVE study, hearing intervention slowed cognitive decline in participants at higher risk, while the overall trial did not show the same clear cognitive benefit. This is promising evidence for a particular group, rather than proof that hearing aids prevent dementia in everyone. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Behavioral

Intermittent fasting changes when people eat, and may also reduce how much they eat. Human research has examined weight and metabolic or ageing-related markers, but those outcomes should not be confused with demonstrated life extension. An important question is whether meal timing adds benefit beyond changes in total food intake, and whether an approach remains appropriate over time. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Frontier

Klotho is a protein studied for links with ageing and brain function. Giving it to aged rhesus monkeys improved performance on a memory task in a small experimental study. That is an animal cognition result, not evidence of human life extension; clinical benefit, delivery and safety in people are separate questions. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Behavioral

A Mediterranean-style diet emphasizes plant foods, olive oil and foods such as nuts and fish. The reanalysed PREDIMED trial found fewer major cardiovascular events in high-risk adults assigned to versions supplemented with olive oil or nuts. That supports cardiovascular prevention in the population studied, rather than proving that one diet reverses ageing or guarantees longer life. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 5, 2026: “Study and Design of New Sustainable Exercise and Dietary-nutritional Programs for the Treatment of Metabolic Disorders in Elderly Women”. Its implications have not yet been summarized in a source-checked review. Read update ↗

AI review not yet available

Experimental off label

Metformin is a diabetes medicine being investigated for effects on ageing-related biology. Laboratory findings and studies in people with metabolic disease make it a plausible research candidate, but they do not establish that otherwise healthy adults live longer by taking it. The key unresolved question is whether it prevents meaningful age-related illness, rather than merely changing laboratory markers. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 27, 2026: “FEAST and HOPE: Redox PSC Pilot Study in PSC”. Its implications have not yet been summarized in a source-checked review. Read update ↗

AI review not yet available

Accessible

Nicotinamide riboside is another way researchers try to raise NAD levels. A small randomized trial in middle-aged and older adults showed that it raises blood NAD, with exploratory findings that motivated further cardiovascular research. Successfully changing a molecule is an early research step; the clinical benefits and implications for lifespan require separate demonstration. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 27, 2026: “FEAST and HOPE: Redox PSC Pilot Study in PSC”. Its implications have not yet been summarized in a source-checked review. Read update ↗

AI review not yet available

Accessible

NMN is a precursor of NAD, a molecule involved in cellular metabolism. Small human trials have shown that supplementation can raise blood NAD and have examined short-term functional outcomes. These trials do not establish that raising NAD makes people live longer, and brief tolerability findings cannot settle the safety of years of use. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 7, 2026: “Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults”. Its implications have not yet been summarized in a source-checked review. Read update ↗

AI review not yet available

Accessible

Omega-3 fatty acids are studied for cardiovascular health, but results vary across populations and preparations. Prescription products, ordinary fish-oil supplements and eating fish are not interchangeable interventions. The useful question is which product improves which clinical outcome in which population, rather than assuming that a change in blood fats means a general longevity benefit. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Frontier

Partial reprogramming tries to restore aspects of youthful cell function by altering gene activity. A landmark mouse study restored aspects of vision, providing evidence that some tissue changes can be modified experimentally. Restoring function in one animal tissue does not establish whole-body rejuvenation in humans; control, delivery and long-term safety are critical translation questions. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Accessible

Preventing and treating gum disease protects the tissues that support teeth and helps preserve oral health. That practical benefit should not depend on a longevity claim. Links between oral health and wider disease are a separate research question; evidence that dental treatment improves gums is not, by itself, evidence that it prevents dementia or extends life. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Behavioral

Reducing protein is not a simple healthy-ageing rule. Protein is needed to maintain muscle, and older adults can respond less strongly to a given amount of dietary protein. Research on nutrient signalling must therefore be balanced against physical function and muscle loss; a proposed ageing mechanism does not establish that eating less protein benefits an older person. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Experimental off label

Rapamycin is a prominent experimental longevity candidate because lifespan extension has been reproduced in the National Institute on Aging’s mouse testing program. That is stronger animal evidence than a single laboratory experiment, but it remains animal evidence. It does not establish an effective, safe life-extension treatment for people or justify translating a mouse regimen into personal use. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Behavioral

Strength training helps maintain muscle, physical function and the ability to manage everyday tasks with age. These are useful health benefits in their own right, especially when combined with aerobic and balance activity. The clearest case is preserving function and independence; a change in muscle strength alone does not measure life extension. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 27, 2026: “Physical Activity Interventions for Sleep Improvement and Sedative-Hypnotic Reduction in Middle-Aged and Older Adults: Investigating the Role of Sarcopenia”. Its implications have not yet been summarized in a source-checked review. Read update ↗

AI review not yet available

Accessible

Frequent sauna use was associated with lower cardiovascular and overall mortality in a long-running Finnish study of men. The finding is interesting, but participants were not randomly assigned to use a sauna: differences in health and lifestyle could help explain the result. It supports further study rather than a promise that sauna sessions extend life. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Frontier

Senolytics aim to remove cells that have entered a persistent damaged state. Human testing is underway, but findings are still limited: an NIA-supported trial in older women found only limited bone-health benefits compared with controls. A promising cellular mechanism should therefore be distinguished from demonstrated prevention of age-related disease or longer life in people. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 23, 2026: “SENolytics to Improve Osteoporosis Therapy: a Randomised Controlled Clinical Trial The SENIOR Trial”. Its implications have not yet been summarized in a source-checked review. Read update ↗

AI-reviewed · not yet expert-reviewed

Sep 26, 2026

Prescription

SGLT2 inhibitors are medicines with benefits for defined metabolic, heart and kidney conditions. Empagliflozin’s indications include reducing serious kidney and cardiovascular outcomes in adults with chronic kidney disease at risk of progression. Those are clinically meaningful outcomes in selected patients, but they do not establish a general anti-ageing benefit for healthy people. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 13, 2026: “Evidence-Based Longevity Interventions and Targeted Engagement (E.L.I.T.E.)”. Its implications have not yet been summarized in a source-checked review. Read update ↗

AI review not yet available

Prescription

The established purpose of shingles vaccination is preventing shingles and its complications. Research suggesting a relationship with lower or later dementia risk adds an interesting question, but this possible additional benefit is separate from the vaccine’s established purpose. Dementia findings should be judged by their study design and should not be presented as guaranteed protection against cognitive decline. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Behavioral

Sleep supports mental and physical health, alertness and day-to-day function. Persistent poor sleep can also signal a treatable condition such as sleep apnea, rather than simply normal ageing. The useful distinction is between improving sleep health and claiming that a particular sleep duration or product will extend lifespan. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 27, 2026: “Physical Activity Interventions for Sleep Improvement and Sedative-Hypnotic Reduction in Middle-Aged and Older Adults: Investigating the Role of Sarcopenia”. Its implications have not yet been summarized in a source-checked review. Read update ↗

AI review not yet available

Behavioral

Stopping smoking is an established way to reduce premature death and risks of heart disease, cancer and lung disease. Benefits occur at any age, including for people who have smoked for many years. This is a direct prevention opportunity with health-outcome evidence, although the size and timing of benefit vary with a person’s smoking history and health. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Behavioral

Loneliness and social isolation are associated with poorer physical and mental health, including heart disease and cognitive decline. Social relationships therefore matter for healthy ageing and quality of life. Much of the risk evidence is observational, so an association cannot tell us precisely how much a particular social activity would change someone’s lifespan. Source ↗ Recently: The latest trial-registry update in our collection is dated Sep 30, 2026: “Immersive Group Dance in Virtual Reality Improves Perceived Social Cohesion in Older Adults: A Technology-Assisted Movement Intervention - A Two-Arm, Parallel-Group Randomized Controlled Trial With Sex-Based Comparison”. Its implications have not yet been summarized in a source-checked review. Read update ↗

AI review not yet available

Accessible

Spermidine is being investigated as a possible way to influence cellular maintenance. Human supplement research includes small, short trials, such as a study examining tolerability and blood chemistry over weeks. Such work can inform further trials, but it cannot establish prevention of age-related disease, long-term safety or life extension. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Prescription

Statins lower cholesterol and can reduce the risk of cardiovascular disease in appropriately selected adults. Their value depends on existing disease, overall cardiovascular risk and age; evidence for starting treatment in older adults without cardiovascular disease is less certain. They are preventive medicines for particular risks, not a general treatment for ageing. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Frontier

Cell therapies have legitimate, specific medical applications, but that does not validate broadly marketed anti-ageing infusions. The FDA warns that unapproved regenerative products can cause serious harm. Each product and indication needs its own clinical evidence; calling something a stem-cell treatment is not evidence of rejuvenation, effectiveness or safety. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI-reviewed · not yet expert-reviewed

Sep 26, 2026

Accessible

Taurine attracted longevity interest, but a key part of its ageing story has been challenged. NIH researchers reported in 2025 that circulating levels did not consistently decline with age and were inconsistently related to health outcomes. That weakens a simple “replace what ageing removes” explanation; it does not, by itself, settle whether supplementation has useful clinical effects. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Prescription

Testosterone therapy is intended for defined medical circumstances, not as a general longevity treatment. In 2025, the FDA revised cardiovascular warnings after the TRAVERSE trial and required warnings about increased blood pressure. This illustrates why evidence must be tied to the treated population: reassuring findings for one outcome do not prove anti-ageing benefit or eliminate other risks. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Frontier

Plasma exchange removes and replaces the liquid part of blood. A randomized human study reported changes in biological-age measurements, attracting interest in ageing applications. Those measurements are indirect endpoints: the study does not establish longer life or prevention of age-related illness, and the burdens and risks of a medical procedure matter alongside biomarker changes. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Accessible

Vitamin D has an established role in bone health, and inadequate levels matter. That does not make extra supplementation a universal ageing treatment: studies of disease prevention in people who already have adequate levels have not consistently supported the broad benefits suggested by observational associations. Correcting a deficiency and trying to extend lifespan are different research questions. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI review not yet available

Behavioral

Aerobic training improves the ability to sustain activity and is part of an established approach to healthy ageing. VO₂ max describes how much oxygen the body can use during intense exercise. It is a fitness measure, not a lifespan clock: improving a test result should not automatically be interpreted as gaining a particular number of years. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 26, 2026: “Effect of Preoperative Resistance and Aerobic Endurance Training on Surgical Outcomes and Evaluation of Patient Compliance With Prehabilitation in Colorectal Surgery: A Randomized Controlled Trial”. Its implications have not yet been summarized in a source-checked review. Read update ↗

AI review not yet available